LATEST NEWS

PUBLIC CONSULTATION ANVISA – single use and reusable medical devices

Date: 01/16/2019

Some medical devices may be used more than once and be reprocessed safely. This practice gives them a longer product life and use, as long as they provide effectiveness and functionality.

Medical devices that may be processed are those that allow repeated cleaning, disinfection or sterilization and that can be reused, given they comply with current regulations. This reprocessing should not be repeated indefinitely: there is a moment at which the quality of the product – in terms of its effectiveness and functionality – no longer corresponds to that required for its use.

For this reason, ANVISA opened Public Consultation 584, on December 20th, 2018, which was published in the Official Gazette on December 21st, 2018, in order to receive comments and suggestions from the general public regarding the text of the proposed resolution which deals with the categorizing of medical devices as single use or reusable. The Public Consultation will be open for 60 days, from January 8th to March 9th, 2019. Suggestions should be sent by electronic form in Portuguese.

Exceptionally, international contributions may be sent through letter to the following address: National Health Surveillance Agency (Ainte) – SIA, Section 5, Special Area 57, Brasília-DF, CEP 71.205-050.

In addition to this specific CP, another one has been open with two other connected themes: The first one (CP 585) is related to the requirements of good practices for the processing of products used in health care assistance. Anvisa’s goal with the proposal of a new RDC is to improve the management of risks associated with the processing of medical devices.

The second one (CP 586) deals with a Normative Instruction (IN) that establishes guidelines for quality assurance in health services and its main purpose is validation, monitoring and controlling the routine of sterilization processes and automated cleaning processes as well as disinfection in its services.

To contribute your opinion go to:
CP 585.
CP 586.

Font: Anvisa Website: http://portal.anvisa.gov.br

MORE NEWS

07/18/2024
  From June 24 to 28, ANVISA participated in the MDSAP Forum and Regulatory Authority Council (RAC) meeting in Essen, Germany. The event gathered representatives from 27 countries, including regulatory authorities, MDSAP auditing organizations, and industry representatives, with notable attendance from Brazilian associations ABIMED and [...]
07/02/2024
  In force since January 2022, RDC 591/2021, which provides for the Unique Device Identification (UDI) system, was amended by ANVISA just days before the deadline for attributing and affixing UDI to risk class IV devices. The amendment was published in RDC 884/2024 on June 1, 2024, and is already in force. According to ANVISA,... Leia [...]
04/12/2024
Marking a significant advancement in regulatory reliance mechanisms, the National Health Surveillance Agency (ANVISA) published Normative Instruction (IN) 290/2024, on April 8, 2024. This normative introduces an optimized procedure for evaluating and deciding on registration petitions for medical devices previously regulated in recognized [...]
03/22/2024
Important Regulatory Update for Manufacturers under MDSAP in Brazil Today, ANVISA has announced a significant regulatory development with the publication of Resolution RDC 850/2024. This regulation brings forth a crucial amendment concerning the validity period of the Brazilian Good Manufacturing Practices (BGMP) Certificate for manufacturers [...]
01/05/2024
Collegiate Board Resolution (RDC) 837/2023, published by ANVISA on December 15th, 2023, brings updates to the rules regarding clinical investigations with medical devices performed in Brazil. Effective immediately from the publication, this resolution aligns Brazilian practices with international standards, providing clearer guidelines for [...]
12/13/2023
On 11 of December 2023, ANVISA published Collegiate Board Resolution – RDC 830/2023, addressing risk classification, registration procedures, as well as labeling requirements and instructions for use of in vitro diagnostic medical devices (IVDs) in Brazil. The new RDC, effective from June 1, 2024, is a comprehensive revision that consolidates [...]
11/28/2023
Public Consultation No. 1.208 will be open to receive contributions until December 9th. In the dynamic landscape of medical device regulations in Brazil, obtaining the Brazilian Good Manufacturing Practices (BGMP) certification is a mandatory request for manufacturers of Class III and Class IV devices seeking Registro. In a recent move towards [...]
03/01/2023
  Starting today – March 1st 2023 – the new Resolution RDC nº 751/2022  comes into force. The Resolution provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. In order to meet the new requirements and procedures, ANVISA has already [...]
09/22/2022
The Collegiate Board Resolution – RDC 751/2022 was published on the 21st of September 2022, which provides for risk classification, Notification and Registro processes, and the requirements for medical devices’ labeling and instructions for use. The new RDC consolidates the risk classification and regularization regimes for all risk [...]